The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 30, 2014
Filed:
Dec. 20, 2012
Applicant:
Rhizen Pharmaceuticals SA, La Chaux-de-Fonds, CH;
Inventors:
Meyyappan Muthuppalaniappan, Hyderabad, IN;
Srikant Viswanadha, Hyderabad, IN;
Gayatri Swaroop Merikapudi, Hyderabad, IN;
Swaroop Kumar V. S. Vakkalanka, La Chaux-de-Fonds, CH;
Assignee:
Rhizen Pharmaceuticals SA, La Chaux-de-Fonds, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 231/12 (2006.01); C07D 417/10 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 403/14 (2006.01); C07D 413/10 (2006.01); C07D 401/04 (2006.01); C07D 403/10 (2006.01); C07D 413/14 (2006.01); C07D 207/327 (2006.01); C07D 401/12 (2006.01); C07D 401/10 (2006.01);
U.S. Cl.
CPC ...
C07D 207/327 (2013.01); C07D 417/14 (2013.01); C07D 403/14 (2013.01); C07D 413/10 (2013.01); C07D 413/12 (2013.01); C07D 231/12 (2013.01); C07D 401/04 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 413/14 (2013.01); C07D 401/12 (2013.01); C07D 401/10 (2013.01); C07D 403/04 (2013.01); C07D 417/12 (2013.01); C07D 401/14 (2013.01); C07D 417/10 (2013.01);
Abstract
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.